NeuroSense reschedules Health Canada meeting to include additional data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/15/2026
- Dow hits record high on Iran deal optimism, lower oil prices
- Fox to acquire Roku for $22 billion to create streaming and live content giant
- SpaceX extends gains premarket after biggest IPO ever values it at $2.1 trillion
- These 2 space stocks were upgraded at KeyBanc today
- Nvidia plans to raise at least $20 billion in bond sale
- This stock is the biggest winner from higher voltages in the Datacenter IT room
- This company's long-term growth remains underappreciated: Wolfe
- Johnson & Johnson shows positive results for TALVEY-DARZALEX drug combination
- Lilly's Jaypirca reduces disease progression risk by 45% in CLL study
- Why does Barclays say it’s time to buy this Spanish stock?
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
March 24, 2026 9:01 AM EDTCAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today provided an update on key regulatory and clinical milestones for its lead asset,... More
